Tumor mutational burden and somatic mutation status to predict disease recurrence in advanced melanoma.

ABSTRACT: Tumor mutational burden (TMB) has recently been identified as a biomarker of response to immune checkpoint inhibitors in many cancers, including melanoma. Co-assessment of TMB with inflammatory markers and genetic mutations may better predict disease outcomes. The goal of this study was to evaluate the potential for TMB and somatic mutations in combination to predict the recurrence of disease in advanced melanoma. A retrospective review of 85 patients with stage III or IV melanoma whose tumors were analyzed by next-generation sequencing was conducted. Fisher's exact test was used to assess differences in TMB category by somatic mutation status as well as recurrence locations. Kaplan-Meier estimates and Cox-proportional regression model were used for survival analyses. The most frequently d

SUBMITTER: Hotz MJ 

PROVIDER: S-EPMC9109603 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature